RU2017134693A - Лекарственное средство - Google Patents
Лекарственное средство Download PDFInfo
- Publication number
- RU2017134693A RU2017134693A RU2017134693A RU2017134693A RU2017134693A RU 2017134693 A RU2017134693 A RU 2017134693A RU 2017134693 A RU2017134693 A RU 2017134693A RU 2017134693 A RU2017134693 A RU 2017134693A RU 2017134693 A RU2017134693 A RU 2017134693A
- Authority
- RU
- Russia
- Prior art keywords
- toll
- receptor agonist
- protein
- drug according
- lag
- Prior art date
Links
- 239000003814 drug Substances 0.000 claims 15
- 229940079593 drug Drugs 0.000 claims 14
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 9
- 239000003970 toll like receptor agonist Substances 0.000 claims 9
- 102000017578 LAG3 Human genes 0.000 claims 7
- 101150030213 Lag3 gene Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 230000028993 immune response Effects 0.000 claims 5
- 230000001939 inductive effect Effects 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940022399 cancer vaccine Drugs 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Claims (28)
1. Лекарственное средство, включающее:
агонист Toll-подобного рецептора и
белок LAG-3, его вариант или производное.
2. Лекарственное средство по п.1 для комбинированного введения:
агониста Toll-подобного рецептора и
белка LAG-3, его варианта или производного.
3. Лекарственное средство по п.1, где агонист Toll-подобного рецептора является агонистом Toll-подобного рецептора 3 или агонистом Toll-подобного рецептора 9.
4. Лекарственное средство по п.1, где агонистом Toll-подобного рецептора является поли-I:C или его соль.
5. Лекарственное средство по п.1, где белок LAG-3, его вариант или производное является слитым белком белка LAG-3 и IgG.
6. Лекарственное средство по п.1, дополнительно включающее вещество для индукции специфичного иммунного ответа по меньшей мере против одного типа раковой клетки.
7. Лекарственное средство по п.6 для комбинированного введения:
агониста Toll-подобного рецептора,
белка LAG-3, его варианта или производного, и
вещества для индукции специфичного иммунного ответа по меньшей мере против одного типа раковой клетки.
8. Лекарственное средство по п.6, где вещество для индукции специфичного иммунного ответа против раковой клетки является полученным из ракового антигена пептидом.
9. Лекарственное средство по п.8, включающее два или более полученных из ракового антигена пептидов.
10. Лекарственное средство по п.1 для применения в противораковой вакцинотерапии.
11. Лекарственное средство по п.10, где лекарственное средство является противоопухолевым средством.
12. Адъювант, включающий:
агонист Toll-подобного рецептора и
белок LAG-3, его вариант или производное,
для применения в индукции специфичного иммунного ответа против раковой клетки.
13. Комбинация, включающая:
агонист Toll-подобного рецептора и
белок LAG-3, его вариант или производное,
для применения в индукции специфичного иммунного ответа против раковой клетки.
14. Лекарственное средство по п.6 для применения в противораковой вакцинотерапии.
15. Лекарственное средство по п.14, где лекарственное средство является противоопухолевым средством.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-078684 | 2015-04-07 | ||
JP2015078684 | 2015-04-07 | ||
JP2015198066 | 2015-10-05 | ||
JP2015-198066 | 2015-10-05 | ||
JP2016-032046 | 2016-02-23 | ||
JP2016032046 | 2016-02-23 | ||
PCT/JP2016/061463 WO2016163489A1 (ja) | 2015-04-07 | 2016-04-07 | 医薬 |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2017134693A true RU2017134693A (ru) | 2019-04-04 |
RU2017134693A3 RU2017134693A3 (ru) | 2019-09-20 |
RU2709015C2 RU2709015C2 (ru) | 2019-12-13 |
Family
ID=57072456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017134693A RU2709015C2 (ru) | 2015-04-07 | 2016-04-07 | Лекарственное средство |
Country Status (12)
Country | Link |
---|---|
US (2) | US10842848B2 (ru) |
EP (2) | EP3281641B1 (ru) |
JP (1) | JP6311094B2 (ru) |
CN (1) | CN107530432B (ru) |
AU (1) | AU2016244570B2 (ru) |
BR (1) | BR112017020404A2 (ru) |
CA (1) | CA2981468A1 (ru) |
DK (1) | DK3281641T3 (ru) |
ES (1) | ES2844049T3 (ru) |
RU (1) | RU2709015C2 (ru) |
TW (1) | TWI738646B (ru) |
WO (1) | WO2016163489A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3925968A3 (en) | 2014-10-07 | 2022-03-02 | Cytlimic Inc. | Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell |
WO2016143816A1 (ja) | 2015-03-09 | 2016-09-15 | 日本電気株式会社 | Gpc3由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
US10842848B2 (en) | 2015-04-07 | 2020-11-24 | Cytlimic Inc. | Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein |
US11291718B2 (en) | 2016-10-11 | 2022-04-05 | Cytlimic Inc. | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196523A (en) | 1985-01-01 | 1993-03-23 | The University Of Southern California | Control of gene expression by glucose, calcium and temperature |
JPH08151396A (ja) | 1994-11-28 | 1996-06-11 | Teijin Ltd | Hla結合性オリゴペプチド及びそれを含有する免疫調節剤 |
EP0893507A1 (en) | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
RS51309B (sr) | 1998-12-23 | 2010-12-31 | Pfizer Inc. | Humana monoklonalna antitela za ctla-4 |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
ES2326114T3 (es) | 2000-09-13 | 2009-10-01 | Multimmune Gmbh | Un peptido de hsp70 estimulador de la actividad de las celulas asesinas naturales (nk) y los usos del mismo. |
KR20040041575A (ko) | 2001-07-31 | 2004-05-17 | 칼 페터 쇠더스트룀 | 면역반응의 모듈화 조성물 및 모듈화 방법 |
AU2003254950A1 (en) | 2002-08-26 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | Peptides and drugs containing the same |
US7387271B2 (en) | 2002-12-30 | 2008-06-17 | 3M Innovative Properties Company | Immunostimulatory combinations |
FR2863890B1 (fr) * | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
ES2427646T5 (es) | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
MX2007014390A (es) * | 2005-05-19 | 2008-02-12 | Glaxosmithkline Biolog Sa | Composicion de vacuna que comprende subunidad b de termo toxina e. coli y antigeno y adyuvante. |
US8053556B2 (en) | 2005-08-09 | 2011-11-08 | Oncotherapy Science, Inc. | Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same |
WO2007119515A1 (ja) | 2006-03-28 | 2007-10-25 | Dainippon Sumitomo Pharma Co., Ltd. | 新規腫瘍抗原ペプチド |
RU2333767C2 (ru) | 2006-03-31 | 2008-09-20 | Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") | Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции |
CN101568550B (zh) | 2006-10-17 | 2012-12-26 | 肿瘤疗法科学股份有限公司 | 用于表达mphosph1或depdc1多肽的癌症的肽疫苗 |
US20100137221A1 (en) | 2007-02-27 | 2010-06-03 | University Utah Research Foundation | Peptides that interact with topoisomerase i and methods thereof |
RS53072B (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1 |
US8742068B2 (en) | 2007-07-06 | 2014-06-03 | Universiteit Utrecht Holding B.V. | Treatment and prevention of inflammatory diseases and autoimmune diseases |
WO2009036349A1 (en) | 2007-09-12 | 2009-03-19 | Anaphore, Inc. | Hsp70-based treatment for autoimmune diseases |
KR100900837B1 (ko) * | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물 |
US9370558B2 (en) * | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
HUE034832T2 (hu) | 2008-12-09 | 2021-12-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására |
CN104136614B (zh) * | 2009-10-06 | 2018-04-06 | 帕纳塞拉实验室有限责任公司 | Toll‑样受体和激动剂用于治疗癌症的用途 |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
JP6138813B2 (ja) | 2011-11-28 | 2017-05-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 抗pd−l1抗体及びその使用 |
IN2014MN01513A (ru) | 2012-02-07 | 2015-09-11 | Jolla Inst Allergy Immunolog | |
US20130217122A1 (en) | 2012-02-21 | 2013-08-22 | The Trustees Of The University Of Pennsylvania | Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library |
WO2013143026A1 (en) | 2012-03-31 | 2013-10-03 | Abmart (Shanghai) Co., Ltd | Peptide and antibody libraries and uses thereof |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
JP2014169280A (ja) | 2013-02-05 | 2014-09-18 | Nitto Denko Corp | 経皮または粘膜投与用ワクチン組成物 |
PT2961388T (pt) * | 2013-03-01 | 2019-07-11 | Astex Pharmaceuticals Inc | Combinações de fármacos |
JP7348708B2 (ja) * | 2014-04-30 | 2023-09-21 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 組み合わせワクチン装置および癌細胞を殺滅する方法 |
EP3925968A3 (en) | 2014-10-07 | 2022-03-02 | Cytlimic Inc. | Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell |
WO2016143816A1 (ja) | 2015-03-09 | 2016-09-15 | 日本電気株式会社 | Gpc3由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
US10842848B2 (en) | 2015-04-07 | 2020-11-24 | Cytlimic Inc. | Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein |
WO2018021400A1 (ja) | 2016-07-27 | 2018-02-01 | 国立大学法人北海道大学 | がん免疫アジュバント |
US11291718B2 (en) | 2016-10-11 | 2022-04-05 | Cytlimic Inc. | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
-
2016
- 2016-04-07 US US15/564,604 patent/US10842848B2/en active Active
- 2016-04-07 ES ES16776655T patent/ES2844049T3/es active Active
- 2016-04-07 TW TW105110968A patent/TWI738646B/zh not_active IP Right Cessation
- 2016-04-07 JP JP2017511073A patent/JP6311094B2/ja active Active
- 2016-04-07 BR BR112017020404-5A patent/BR112017020404A2/pt not_active IP Right Cessation
- 2016-04-07 EP EP16776655.9A patent/EP3281641B1/en active Active
- 2016-04-07 RU RU2017134693A patent/RU2709015C2/ru active
- 2016-04-07 CA CA2981468A patent/CA2981468A1/en not_active Abandoned
- 2016-04-07 AU AU2016244570A patent/AU2016244570B2/en active Active
- 2016-04-07 EP EP20204940.9A patent/EP3797794A1/en not_active Withdrawn
- 2016-04-07 DK DK16776655.9T patent/DK3281641T3/da active
- 2016-04-07 CN CN201680020132.8A patent/CN107530432B/zh not_active Expired - Fee Related
- 2016-04-07 WO PCT/JP2016/061463 patent/WO2016163489A1/ja active Application Filing
-
2020
- 2020-07-22 US US16/935,534 patent/US11491204B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN107530432A (zh) | 2018-01-02 |
EP3797794A1 (en) | 2021-03-31 |
TW201642907A (zh) | 2016-12-16 |
ES2844049T3 (es) | 2021-07-21 |
US20180071362A1 (en) | 2018-03-15 |
AU2016244570B2 (en) | 2020-08-27 |
JPWO2016163489A1 (ja) | 2017-12-07 |
US20210000916A1 (en) | 2021-01-07 |
EP3281641A4 (en) | 2018-12-19 |
DK3281641T3 (da) | 2021-01-18 |
RU2017134693A3 (ru) | 2019-09-20 |
AU2016244570A1 (en) | 2017-10-05 |
EP3281641B1 (en) | 2020-12-16 |
CN107530432B (zh) | 2021-04-27 |
CA2981468A1 (en) | 2016-10-13 |
TWI738646B (zh) | 2021-09-11 |
EP3281641A1 (en) | 2018-02-14 |
WO2016163489A1 (ja) | 2016-10-13 |
US10842848B2 (en) | 2020-11-24 |
JP6311094B2 (ja) | 2018-04-18 |
RU2709015C2 (ru) | 2019-12-13 |
US11491204B2 (en) | 2022-11-08 |
BR112017020404A2 (pt) | 2018-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
EA201992664A2 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака | |
BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
EA202191027A2 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
EA201891074A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии хлл и других видов рака | |
EA201891638A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака | |
NZ734197A (en) | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers | |
EA201691023A1 (ru) | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством | |
RU2017134693A (ru) | Лекарственное средство | |
EA201792531A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии и способы получения каркасов для применения при лечении рака поджелудочной железы и других видов рака | |
JP2015533376A5 (ru) | ||
EA201790239A1 (ru) | Молекула-носитель для антигенов | |
EA201892443A1 (ru) | Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови | |
RU2014102941A (ru) | Вакцинная композиция для введения через слизистую оболочку | |
RU2019113989A (ru) | Лекарственное средство | |
WO2015140172A3 (en) | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
NZ730708A (en) | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof | |
BR112017027653A2 (pt) | método para induzir a resposta de memória t precoce com vacina anti-tumoral de peptídeos curtos | |
WO2015149016A3 (en) | Breast and ovarian cancer vaccines | |
EA202190186A1 (ru) | Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака | |
WO2015130488A3 (en) | Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection | |
EA201892499A1 (ru) | Новые пептиды, комбинация пептидов в качестве мишеней и средств для применения в иммунотерапии рака желчного пузыря и холангиокарциномы и других видов рака | |
EA202190241A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии хлл и других видов рака | |
EA201992860A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл), мелкоклеточного рака легких (мрл) и других видов рака | |
EA202190465A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака |